Last updated on May 2020

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer


Brief description of study

The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.

Clinical Study Identifier: NCT03785925

Find a site near you

Start Over

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »

Local Institution - Madrid

Pozuelo De Alarcón, Spain
3.73miles
  Connect »